Viridian Therapeutics (VRDN US)
VRDN US$24.80
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 24.80
- Change
- ▲ 0.53 (2.18)
- Bid / Ask
- 21.04 - 24.80
- Volume
- 284,571
- Turnover
- 5,094,123
- Open
- 24.35
- Day Range
- 24.28 - 25.31
- VWAP
- 24.71
- Prev Close
- 24.27
- Last Trade
- 29/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 113,292,269
- NTA/Share
- 7.09
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 70.85
- EBITDA
- -364.59
- Profit
- -342.60
- Earnings Per Share (EPS)
- -3.32
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 2,809.65
- Price to Earnings Ratio (P/E)
- -7.29
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 237.64
- EBITDA
- —
- Profit
- -364.04
- Earnings Per Share (EPS)
- -3.17
- Dividend Per Share (DPS)
- —
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- None
- Financial Health
- Moderate
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 22 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 17.05 Fair value 31.79 One-star price 59.29
Morningstar Quantitative Rating as of 22 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 31.79
- Price / Fair Value
- 0.72
- Valuation
- Undervalued
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 22 OCT 2026. The slider runs from the five-star price (17.05) to the one-star price (59.29).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 22.81 |
| Price - 12 month high | 34.25 |
| Price - 12 month low | 13.19 |
| Pricing date | 21 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 2.22 |
| Market capitalization | 2,585.33 |
| 12 Month High price date | 14 JAN 2026 |
| 12 Month Low price date | 29 APR 2026 |
| Volume - avg. trading volume for the last 3 months | 1.79 |
| Price - 1 Day % Change | -0.87% |
| Price - 13 week price percent change | 18.99% |
| Price - 26 week price percent change | 59.18% |
| Price - 5 Day % Change | 16.62% |
| Price - 52 week price percent change | 4.16% |
| Price - YTD price percent change | -26.47% |
| Price % Change Month To Date | 3.12% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | -3.320 |
| EPS excluding extraordinary items - trailing 12 month | -3.390 |
| EPS Normalized - most recent fiscal year | -2.789 |
| Revenue/share - most recent fiscal year | 0.835 |
| Revenue/share - trailing 12 month | 0.736 |
| Book value per share - most recent fiscal year | 5.795 |
| Book value per share - most recent quarter | 4.981 |
| Book value (tangible) per share - most recent fiscal year | 7.092 |
| Book value (tangible) per share - most recent quarter | 5.759 |
| Cash per share - most recent fiscal year | 2.086 |
| Cash per share - most recent quarter | 1.457 |
| Cash Flow per share - most recent fiscal year | -3.531 |
| Cash Flow per share - trailing 12 month | -3.428 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | -4.147 |
| EPS Basic excluding extraordinary items - most recent fiscal year | -3.320 |
| EPS Basic excluding extraordinary items - trailing 12 month | -3.390 |
| EPS including extraordinary items - most recent fiscal year | -3.320 |
| EPS including extraordinary items - trailing 12 month | -3.370 |
| Free Cash Flow per share - trailing 12 month | -3.446 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | — |
| P/E Normalized, most recent fiscal year | — |
| Price to sales - most recent fiscal year | 31.01 |
| Price to Tangible Book - most fiscal year | 4.67 |
| Price to Free Cash Flow per Share - most recent fiscal year | — |
| Price to Cash Flow per share - trailing 12 month | — |
| Price to Book - most recent fiscal year | 4.58 |
| P/E excluding extraordinary items high, trailing 12 months | — |
| P/E excluding extraordinary items low, trailing 12 months | — |
| Net Debt, LFI | -738.65 |
| Net Debt, LFY | -823.96 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | -299.92 |
| LT debt/equity - most recent fiscal year | 6.92% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 7.02% |
| LT debt/equity - most recent quarter | 36.57% |
| Total debt/total equity - most recent quarter | 36.68% |
| Free Cash Flow - trailing 12 month | -332.84 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 70.85 |
| Revenue - trailing 12 month | 71.13 |
| EBITD - most recent fiscal year | -364.59 |
| EBITD - trailing 12 month | -400.57 |
| Earnings before taxes - most recent fiscal year | -342.60 |
| Earnings before taxes - trailing 12 month | -386.97 |
| Net Income available to common - most recent fiscal year | -342.60 |
| Net Income available to common - trailing 12 months | -421.93 |
| Earnings before taxes Normalized - most recent fiscal year | -297.60 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | -2.83 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | -483.57% |
| Net Profit Margin % - trailing 12 month | -544.06% |
| Operating margin - 1st historical fiscal year | -512.91% |
| Operating margin - trailing 12 month | -569.68% |
| Pretax margin - trailing 12 month | -544.06% |
| Pretax margin - 1st historical fiscal year | -483.57% |
| Operating Margin - 5 year average | -38,167.24% |
| Pretax Margin - 5 year average | -35,118.30% |
| Free Operating Cash Flow/Revenue, 5 Year Average | -30,882.52% |
| Free Operating Cash Flow/Revenue, TTM | -467.94% |
| Net Profit Margin - 5 year average | -35,118.30% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | -49.48% |
| Return on average assets - trailing 12 month | -49.04% |
| Return on average equity - most recent fiscal year | -80.47% |
| Return on average equity - trailing 12 month | -84.18% |
| Return on average assets - 5 year average | -53.09% |
| Return on average equity - 5 year average | -159.65% |
| Net Income/employee - most recent fiscal year | -1,359,527.78 |
| Revenue/employee - most recent fiscal year | 281,146.83 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 132.18% |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | 23.13% |
| Growth rate% - Revenue, 3 year | 241.95% |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | — |
| Capital Spending growth rate, 5 year | 63.78% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | 2028 | 2029 | ||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibodytargeting IGF-1R intravenously administered for the treatment of TED.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
